Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06252616 phase 2 study in ambulatory boys with Duchenne muscular dystrophy
2014-002072-92Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Sep 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing PF-06252616 multiple ascending dose with Placebo (2 arms). Primary endpoint: Safety. Started Sep 2014; status: terminated.
02
Drugs
domagrozumab
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2014-002072-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002072-92.